tiprankstipranks
The Fly

Taysha Gene Therapies initiated with an Overweight at Piper Sandler

Taysha Gene Therapies initiated with an Overweight at Piper Sandler

Piper Sandler initiated coverage of Taysha Gene Therapies with an Overweight rating and $9 price target. The company’s lead asset, TSHA-102 , is poised to transform the treatment paradigm for Rett syndrome a rare, genetic neurodevelopmental disorder with a high unmet need, despite the existence of an approved therapy, the analyst tells investors in a research note. With “further derisking data” anticipated near term, the stock is set to “inflect meaningfully higher” as soon as mid-2024, with additional drivers toward year-end, says Piper.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com